Streetbeat News

Regulatory

USO

The Kuwait Oil Ministry has reaffirmed its commitment to OPEC decisions, emphasizing adherence to market quotas and oil production limits. This statement underlines Kuwait's support for OPEC's efforts to stabilize the oil market.

Portfolio Pulse from Charles Gross

November 27, 2023 | 3:24 pm

BNBUSD

Changpeng Zhao, former CEO of Binance, is disputing the U.S. government's claim that he is a flight risk and should have his bail terms modified. Despite holding citizenship in two countries, including the UAE, Zhao argues that his guilty plea to charges related to inadequate anti-money laundering measures at Binance and his lack of criminal history negate the flight risk. The court previously ruled in his favor, and Zhao is responding to the government's request for reassessment of his release conditions. The legal document emphasizes that the bail conditions set are sufficient to ensure compliance.

Portfolio Pulse from Murtuza Merchant

November 27, 2023 | 3:07 pm

USDCUSD

Circle, the issuer of the USDC stablecoin, has partnered with SBI Holdings to expand the use of USDC and Circle's Web3 services in Japan. The collaboration aims to ensure compliance with stablecoin regulations and seeks approvals for SBI VC Trade Co to operate as an electronic payment instruments service. SBI Shinsei Bank Ltd. will provide banking services to support stablecoin access and liquidity in Japan. The partnership aligns with Japan's revised Payment Services Act and SBI's digital asset strategy.

Portfolio Pulse from Khyathi Dalal

November 27, 2023 | 2:54 pm

AWH

Aspira Women's Health has received the final crosswalk pricing determination from the Centers for Medicare & Medicaid Services (CMS). CMS has set the 2024 price for Aspira's OvaWatchSM test at $897 per test.

Portfolio Pulse from Bill Haddad

November 27, 2023 | 2:48 pm

TCBP

TC Biopharm's stock price has risen following the announcement that the FDA has cleared the Phase 1B Investigational New Drug (IND) application for TCB-008, a treatment for Acute Myeloid Leukemia.

Portfolio Pulse from Benzinga Newsdesk

November 27, 2023 | 2:47 pm

EIS

Talks of extending the truce between Israel and Hamas are underway, with international support. 58 hostages have been released, and the fate of additional American hostages in Gaza is uncertain. Elon Musk visited an Israeli kibbutz attacked by Hamas and agreed not to activate Starlink over Gaza without Israel's approval. Israeli stocks are slightly down, while the shekel is up. The iShares MSCI Israel ETF (EIS) is expected to resume trading after a four-week winning streak.

Portfolio Pulse from Piero Cingari

November 27, 2023 | 2:36 pm

PLSE

Pulse Biosciences announced it has received all necessary regulatory approvals and completed required activities to begin its planned catheter ablation feasibility study, with the first procedures scheduled for mid-December 2023.

Portfolio Pulse from Benzinga Newsdesk

November 27, 2023 | 2:21 pm

RDHL

Redhill Biopharma's stock is trading higher following the announcement that the FDA has granted Talicia five years of market exclusivity.

Portfolio Pulse from Benzinga Newsdesk

November 27, 2023 | 2:17 pm

REGN

SNY

Regeneron Pharmaceuticals Inc and Sanofi SA announced positive results from the second Phase 3 trial (NOTUS) of Dupixent for treating COPD, showing significant reduction in exacerbations and improvements in lung function. The EMA is reviewing Dupixent for COPD, and the companies plan to submit trial data to the FDA by year-end. Interim analysis results will be the primary analysis for the trial. Sanofi also plans to spin off its consumer healthcare business to focus on innovative medicines and vaccines. REGN shares closed at $798.30, and SNY stock is up 0.89% at $47.60 in premarket trading.

Portfolio Pulse from Vandana Singh

November 27, 2023 | 2:17 pm

RDHL

RedHill Biopharma Ltd's stock (NASDAQ:RDHL) surged over 100% after the FDA granted five years' market exclusivity for its gastrointestinal drug Talicia under the GAIN Act QIDP designation. Talicia, a treatment for H. pylori infection, also received approval for a more flexible dosing regimen. The drug is protected by intellectual property until 2034, adding to its three years' exclusivity for FDA approval under section 505(b)(2).

Portfolio Pulse from Vandana Singh

November 27, 2023 | 2:15 pm